Uo Medicina Ocologica Ospedale Di Carpri e Mirandola, Azienda USL di Modena Trials

Uo Medicina Ocologica Ospedale Di Carpri e Mirandola, Azienda USL di Modena	Welcome, Profile Billing Logout

Uo Medicina Ocologica Ospedale Di Carpri e Mirandola, Azienda USL di Modena

Welcome, Profile Billing Logout

1 Trial

2 Trials

Active Trials

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Artioli, Fabrizio

ROME, NCT04591431 / 2018-002190-21: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Active, not recruiting

400

Europe

Erlotinib, Trastuzumab, Trastuzumab emtansine, Pertuzumab, Lapatinib, Everolimus, Vemurafenib, Cobimetinib, Alectinib, Brigatinib, Palbociclib, Ponatinib, Vismogedib, Itacitinib, Ipatasertib, Entrectinib, Atezolizumab, Nivolumab, Ipilimumab, Pemigatinib, Oncology Drugs, Pralsetinib, Selpercatinib, Talazoparib, Tepotinib, Alpelisib

Fondazione per la Medicina Personalizzata

Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer

12/24

06/25

BDMO, NCT06367491: National Database of Bone Metastases

Recruiting

N/A

800

Europe

Registration in a database

Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori

Bone Metastases

01/30

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites